Sera Prognostics, Inc.
NASDAQ•SERA
CEO: Ms. Evguenia Lindgardt M.B.A.
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 2021-07-15
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Contact Information
2749 East Parleys Way, Suite 200, Salt Lake City, UT, 84109, United States
801-990-0520
Market Cap
$121.91M
P/E (TTM)
-4.9
25.7
Dividend Yield
--
52W High
$6.92
52W Low
$1.37
52W Range
Rank56Top 81.7%
2.5
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Financial Dashboard
Q3 2025 Data
Revenue
$16.00K-44.83%
4-Quarter Trend
EPS
-$0.16-33.33%
4-Quarter Trend
FCF
-$6.59M-9.94%
4-Quarter Trend
Earnings Highlights
Key Highlights
No Data Available
Risk Factors
No Data Available
Outlook
No Data Available
Peer Comparison
Revenue (TTM)
LUCD
DCGO
PREGross Margin (Latest Quarter)
VTGN
OVID
ARMPKey Metrics
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-12.6%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Research & Insights
Next earnings:Mar 18, 2026
EPS:-$0.17
|Revenue:-
Reports
All Years